glyburide has been researched along with Neoplasms in 14 studies
Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide
glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Excerpt | Relevance | Reference |
---|---|---|
"Treatment with glibenclamide could be associated with higher mortality for cardiovascular diseases and malignancies, in comparison with gliclazide." | 3.74 | Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. ( Balzi, D; Barchielli, A; Buiatti, E; Lamanna, C; Mannucci, E; Marchionni, N; Masotti, G; Monami, M, 2007) |
"Metformin, a first-line medication for type 2 diabetes mellitus, arouses growing concerns on its anti-cancer effect." | 2.55 | Enemies or weapons in hands: investigational anti-diabetic drug glibenclamide and cancer risk. ( Gao, R; Xu, W; Yang, T, 2017) |
"It is pivotal and remains challenge for cancer precision treatment to identify the survival outcome interactions between genes, cells and drugs." | 1.62 | siGCD: a web server to explore survival interaction of genes, cells and drugs in human cancers. ( Cui, X; Han, L; Li, Y; Liu, Y; Song, B; Sun, W; Wang, H; Zhang, Y; Zhou, W, 2021) |
" In secondary analyses, duration- and dose-response relationships were observed, with longer cumulative durations and cumulative doses associated with an increased risk of any cancer (>36 months: HR 1." | 1.42 | The Use of Glyburide Compared With Other Sulfonylureas and the Risk of Cancer in Patients With Type 2 Diabetes. ( Azoulay, L; Majdan, A; Tuccori, M; Wu, JW; Yin, H, 2015) |
"Hyperglycaemia is a risk factor for cancer and some sulphonylureas have anti-oxidant properties." | 1.36 | Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry. ( Chan, JC; Chow, CC; Ko, GT; Kong, AP; Luk, AO; Ma, RC; Ng, VW; Ozaki, R; So, WY; Tong, PC; Yang, X; Yu, LW, 2010) |
" At the same time about 1/3 of these serious adverse drug reactions (ADR) was found to have been reported to the ADR-register." | 1.27 | Drug utilization and morbidity statistics for the evaluation of drug safety in Sweden. ( Westerholm, B; Wiholm, BE, 1984) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (7.14) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (28.57) | 29.6817 |
2010's | 7 (50.00) | 24.3611 |
2020's | 2 (14.29) | 2.80 |
Authors | Studies |
---|---|
Diamandis, P | 1 |
Wildenhain, J | 1 |
Clarke, ID | 1 |
Sacher, AG | 1 |
Graham, J | 1 |
Bellows, DS | 1 |
Ling, EK | 1 |
Ward, RJ | 1 |
Jamieson, LG | 1 |
Tyers, M | 1 |
Dirks, PB | 1 |
Lin, R | 1 |
Elf, S | 1 |
Shan, C | 1 |
Kang, HB | 1 |
Ji, Q | 1 |
Zhou, L | 1 |
Hitosugi, T | 1 |
Zhang, L | 1 |
Zhang, S | 1 |
Seo, JH | 1 |
Xie, J | 1 |
Tucker, M | 1 |
Gu, TL | 1 |
Sudderth, J | 1 |
Jiang, L | 2 |
Mitsche, M | 1 |
DeBerardinis, RJ | 1 |
Wu, S | 1 |
Li, Y | 2 |
Mao, H | 1 |
Chen, PR | 1 |
Wang, D | 1 |
Chen, GZ | 1 |
Hurwitz, SJ | 1 |
Lonial, S | 1 |
Arellano, ML | 1 |
Khoury, HJ | 1 |
Khuri, FR | 1 |
Lee, BH | 1 |
Lei, Q | 1 |
Brat, DJ | 1 |
Ye, K | 1 |
Boggon, TJ | 1 |
He, C | 1 |
Kang, S | 1 |
Fan, J | 1 |
Chen, J | 1 |
Zhou, Y | 1 |
Song, M | 1 |
Xie, D | 1 |
Yan, S | 1 |
Yu, S | 1 |
Xie, S | 1 |
Cai, M | 1 |
Li, H | 1 |
Shang, L | 1 |
Yuan, C | 1 |
Huang, M | 1 |
Li, J | 1 |
Xu, P | 1 |
Cui, X | 1 |
Han, L | 1 |
Liu, Y | 1 |
Sun, W | 1 |
Song, B | 1 |
Zhou, W | 1 |
Zhang, Y | 1 |
Wang, H | 1 |
Gao, R | 1 |
Yang, T | 1 |
Xu, W | 1 |
Tokunaga, T | 1 |
Ando, T | 1 |
Suzuki-Karasaki, M | 1 |
Ito, T | 1 |
Onoe-Takahashi, A | 1 |
Ochiai, T | 1 |
Soma, M | 1 |
Suzuki-Karasaki, Y | 1 |
Bo, S | 1 |
Castiglione, A | 1 |
Ghigo, E | 1 |
Gentile, L | 1 |
Durazzo, M | 1 |
Cavallo-Perin, P | 1 |
Ciccone, G | 1 |
Lamos, EL | 1 |
Stein, SA | 1 |
Davis, SN | 1 |
Tuccori, M | 1 |
Wu, JW | 1 |
Yin, H | 1 |
Majdan, A | 1 |
Azoulay, L | 1 |
Monami, M | 2 |
Lamanna, C | 2 |
Balzi, D | 2 |
Marchionni, N | 2 |
Mannucci, E | 2 |
Yang, X | 1 |
So, WY | 1 |
Ma, RC | 1 |
Yu, LW | 1 |
Ko, GT | 1 |
Kong, AP | 1 |
Ng, VW | 1 |
Luk, AO | 1 |
Ozaki, R | 1 |
Tong, PC | 1 |
Chow, CC | 1 |
Chan, JC | 1 |
Barchielli, A | 1 |
Masotti, G | 1 |
Buiatti, E | 1 |
Han, X | 1 |
Wang, F | 1 |
Yao, W | 1 |
Xing, H | 1 |
Weng, D | 1 |
Song, X | 1 |
Chen, G | 1 |
Xi, L | 1 |
Zhu, T | 1 |
Zhou, J | 1 |
Xu, G | 1 |
Wang, S | 1 |
Meng, L | 1 |
Iadecola, C | 1 |
Wang, G | 1 |
Ma, D | 1 |
Wiholm, BE | 1 |
Westerholm, B | 1 |
3 reviews available for glyburide and Neoplasms
Article | Year |
---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Enemies or weapons in hands: investigational anti-diabetic drug glibenclamide and cancer risk.
Topics: Animals; ATP-Binding Cassette Transporters; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycem | 2017 |
Sulfonylureas and meglitinides: historical and contemporary issues.
Topics: Animals; Benzamides; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Glyburide; History, 20th | 2013 |
11 other studies available for glyburide and Neoplasms
Article | Year |
---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
Structural Dynamics-Driven Discovery of Anticancer and Antimetastatic Effects of Diltiazem and Glibenclamide Targeting Urokinase Receptor.
Topics: Diltiazem; Glyburide; Humans; Ligands; Neoplasms; Urokinase-Type Plasminogen Activator | 2023 |
siGCD: a web server to explore survival interaction of genes, cells and drugs in human cancers.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Drug Synergism; ErbB Receptors; Gene Expression Regulation | 2021 |
Plasma-stimulated medium kills TRAIL-resistant human malignant cells by promoting caspase-independent cell death via membrane potential and calcium dynamics modulation.
Topics: Calcium; Caspase 3; Caspase 7; Cell Death; Cell Line, Tumor; Culture Media; Dose-Response Relationsh | 2018 |
Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
Topics: Adult; Aged; Cardiovascular Diseases; Cause of Death; Cohort Studies; Confounding Factors, Epidemiol | 2013 |
The Use of Glyburide Compared With Other Sulfonylureas and the Risk of Cancer in Patients With Type 2 Diabetes.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Mal | 2015 |
Sulphonylureas and cancer: a case-control study.
Topics: Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Gliclazide; Glybur | 2009 |
Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry.
Topics: Aged; Asian People; Cohort Studies; Diabetes Mellitus, Type 2; Female; Gliclazide; Glipizide; Glybur | 2010 |
Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality.
Topics: Aged; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; | 2007 |
Heat shock proteins and p53 play a critical role in K+ channel-mediated tumor cell proliferation and apoptosis.
Topics: 4-Aminopyridine; Alkaloids; Apoptosis; bcl-2-Associated X Protein; Benzylisoquinolines; Calcium Chan | 2007 |
Drug utilization and morbidity statistics for the evaluation of drug safety in Sweden.
Topics: Acidosis; Aged; Anti-Infective Agents, Urinary; Biguanides; Congenital Abnormalities; Contraceptives | 1984 |